Breast and Gynecologic Cancer Advances | Women’s Cancer Series

Sentinel Lymph Node Biopsies &
Who Should Have Them

Making Progress in
Ovarian Cancer

Heated Intraperitoneal Chemotherapy (HIPEC)
for Metastatic Gynecologic Cancer

Managing Triple-Negative &
Hereditary Breast Cancer

SPEAKERS

Melinda L. Telli, MD

Medical Oncologist
Associate Professor, Medicine
Director, Breast Cancer Program, Stanford Cancer Institute

Dr. Melinda L. Telli leads the Breast Cancer Program and specializes in the treatment of triple-negative and hereditary breast cancers. Her research focuses on the validation of homologous cheap replica rolex day date 36mm mens 118239 stainless steel watch recombination deficiency biomarkers to identify patients with sporadic triple-negative breast cancer and the development of PARP inhibitor therapy for BRCA1 and BRCA2 mutation-associated cancers.

Oliver Dorigo, MD, PhD

Gynecologic Oncologist
Associate Professor, Obstetrics & Gynecology
Director, Gynecologic Cancer Program, Stanford Cancer Institute

Dr. Oliver Dorigo leads the Gynecologic Cancer Program and specializes in the treatment of ovarian, cervical, endometrial, vaginal, and vulvar cancers. He is dedicated to the expansion of the clinical trials program and the development of novel therapies for ovarian cancer in the laboratory. In his surgical practice, Dr. Dorigo emphasizes use of minimally invasive technologies.

Kimberly Sue Stone, MD

Breast Surgeon
Clinical Assistant Professor, Surgery
Director, Stanford Medicine Network Breast Oncology Program

Dr. Kimberly Sue Stone specializes in breast surgical oncology and treats all conditions related to breast health. She is skilled in total skin and nipple sparing mastectomy, wireless lumpectomy, benign breast disease excisions, axillary surgery, sentinel lymph node biopsy, and lymph node dissection. Dr. Stone believes patient empowerment and education are at the heart of excellent care.

Amer Karam, MD

Gynecologic Oncologist
Clinical Professor, Obstetrics & Gynecology

Dr. Amer Karam specializes in the treatment of gynecologic cancers, including cervical, vaginal, vulvar, ovarian, fallopian tube, and peritoneal cancer. He is also a leader in HIPEC treatment, an innovative vapesstores treatment that delivers high dose chemotherapy directly to the site of tumor during surgery. Dr. Karam has a strong interest in minimally invasive and robotic surgery.

RESOURCES

The Stanford Women’s Cancer Center has clinics in Emeryville, Palo Alto, Pleasanton, San Jose, and Turlock. The Breast Cancer Program and the Gynecologic Cancer Program provide specialized expertise in treating every stage and subtype of breast and gynecologic cancers and are affiliate with the Stanford Cancer Institute, an NCI-Designated Comprehensive Cancer Center.

Sentinel Lymph Node Biopsies & Who Should Have Them

Making Progress in Ovarian Cancer

Heated Intraperitoneal Chemotherapy (HIPEC)for Metastatic Gynecologic Cancer

Managing Triple-Negative & Hereditary Breast Cancer